Related Experiment Video
Updated: May 22, 2025
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Research Progress in Immune Checkpoint Inhibitors for Relapsed and Refractory Malignant Gonadal Germ Cell Tumors
1Department of Obstetrics and Gynecology,National Clinical Research Center for Obstetrics and Gynecology, PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Abstract:
Germ cell tumors typically occur in the gonadal regions,characterized by high malignancy and rapid progression.Due to their high sensitivity to chemotherapy,the cure rate is generally high.However,a portion of patients still succumb to chemotherapy resistance and disease progression.The use of immune checkpoint inhibitors has significantly improved the prognosis for various solid tumors,while the immune mechanisms and efficacy of immunotherapy in germ cell tumors remain understudied.Whether relapsed and refractory germ cell tumors can benefit from immune checkpoint inhibitors remains to be investigated.In this review,we summarize the immune-related mechanisms,case reports,and clinical trials of immunotherapy in germ cell tumors to assess the effectiveness of this therapy,providing a reference for future basic research and clinical practice.
Insights
Germ cell tumors can be aggressive, but immunotherapy, particularly immune checkpoint inhibitors, shows promise for resistant cases. Further research is needed to understand its full potential in treating these rare cancers.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Germ cell tumors (GCTs) are highly malignant and progress rapidly, often originating in gonadal regions.
- While chemotherapy is effective for many GCTs, a subset of patients develop resistance, leading to disease progression.
- The role of immunotherapy, specifically immune checkpoint inhibitors (ICIs), in GCTs is not well-established, despite their success in other solid tumors.
Purpose of the Study:
- To review the current understanding of immune mechanisms in GCTs.
- To assess the efficacy and potential benefits of immune checkpoint inhibitors for GCT patients, especially those with relapsed or refractory disease.
- To provide a reference for future research and clinical application of immunotherapy in GCTs.
Main Methods:
- Literature review of immune-related mechanisms in GCTs.
- Analysis of case reports on immunotherapy for GCTs.
- Examination of ongoing and completed clinical trials involving ICIs in GCTs.
Main Results:
- The review synthesizes existing data on the immunological aspects of GCTs.
- Evidence from case reports and early clinical trials suggests potential efficacy of ICIs in a subset of GCT patients.
- Significant gaps remain in understanding the precise immune mechanisms and predicting response to immunotherapy in GCTs.
Conclusions:
- Immunotherapy, including immune checkpoint inhibitors, represents a potential therapeutic avenue for patients with relapsed or refractory germ cell tumors.
- Further investigation into the immune landscape of GCTs and robust clinical trials are crucial to define the role of immunotherapy.
- This review highlights the need for continued research to optimize immunotherapy strategies for improved GCT patient outcomes.
More Related Videos
07:46Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells
Published on: October 13, 2023
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
